An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy

被引：11

作者：

Bisogno, Gianni ^{[1
]}

Hawkins, Douglas S. ^{[2
]}

机构：

[1] Univ Padua, Dept Womens & Childrens Hlth, Hematol Oncol Div, Via Giustiniani 3, I-35128 Padua, Italy

[2] Univ Washington, Seattle Childrens Hosp, Fred Hutchinson Canc Res Ctr, Div Hematol Oncol, Seattle, WA 98195 USA

来源：

PEDIATRIC BLOOD & CANCER | 2020年 / 67卷 / 05期

关键词：

chemotherapy duration; maintenance; rhabdomyosarcoma; soft tissue sarcoma; SOFT-TISSUE SARCOMA; LOW-RISK RHABDOMYOSARCOMA; INTERGROUP RHABDOMYOSARCOMA; NONMETASTATIC RHABDOMYOSARCOMA; INTERNATIONAL-SOCIETY; PEDIATRIC-ONCOLOGY; PROGNOSTIC-FACTORS; POOLED ANALYSIS; CHILDHOOD; ADOLESCENCE;

D O I：

10.1002/pbc.28174

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical trials have tested different chemotherapy regimens to improve outcome for patients with rhabdomyosarcoma (RMS), but therapy duration has never been explicitly evaluated. North American trials evolved from longer (104 weeks) to shorter duration (24-42 weeks). In Europe, treatment duration similarly evolved from 35 to 48 to 22 weeks for lower risk patients and from 56 to 72 to 27 weeks for higher risk patients. There was no evidence that chemotherapy duration influenced outcome over time. The recent RMS2005 trial showed an improved survival with the addition of 24 weeks of low-dose chemotherapy. Treatment duration remains a question to be addressed in future trials.

引用

页数：7

共 34 条

[11] Cooperative Trial CWS-91 for Localized Soft Tissue Sarcoma in Children, Adolescents, and Young Adults [J].

Dantonello, Tobias M. ;

Int-Veen, Christoph ;

Harms, Dieter ;

Leuschner, Ivo ;

Schmidt, Bernhard F. ;

Herbst, Manfred ;

Juergens, Heribert ;

Scheel-Walter, Hans-Gerhard ;

Bielack, Stefan S. ;

Klingebiel, Thomas ;

Dickerhoff, Roswitha ;

Kirsch, Sylvia ;

Brecht, Ines ;

Schmelzle, Rainer ;

Greulich, Michael ;

Gadner, Helmut ;

Greiner, Jeanette ;

Marky, Ildiko ;

Treuner, Joern ;

Koscielniak, Ewa .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1446-1455

[12] Paratesticular rhabdomyosarcoma: Report from the Italian and German Cooperative Group [J].

Ferrari, A ;

Bisogno, G ;

Casanova, M ;

Meazza, C ;

Piva, L ;

Cecchetto, G ;

Zanetti, I ;

Pilz, T ;

Mattke, A ;

Treuner, J ;

Carli, M .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :449-455

[13] Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84 [J].

Flamant, F ;

Rodary, C ;

Rey, A ;

Praquin, MT ;

Sommelet, D ;

Quintana, E ;

Theobald, S ;

Brunat-Mentigny, M ;

Otten, J ;

Voute, PA ;

Habrand, JL ;

Martelli, H ;

Barrett, A ;

Terrier-Lacombe, MJ ;

Oberlin, O .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (07) :1050-1062

[14] Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group [J].

Hawkins, Douglas S. ;

Chi, Yueh-Yun ;

Anderson, James R. ;

Tian, Jing ;

Arndt, Carola A. S. ;

Bomgaars, Lisa ;

Donaldson, Sarah S. ;

Hayes-Jordan, Andrea ;

Mascarenhas, Leo ;

McCarville, Mary Beth ;

McCune, Jeannine S. ;

McCowage, Geoff ;

Million, Lynn ;

Morris, Carol D. ;

Parham, David M. ;

Rodeberg, David A. ;

Rudzinski, Erin R. ;

Shnorhavorian, Margarett ;

Spunt, Sheri L. ;

Skapek, Stephen X. ;

Teot, Lisa A. ;

Wolden, Suzanne ;

Yock, Torunn I. ;

Meyer, William H. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (27) :2770-+

[15] Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas [J].

Hawkins, Douglas S. ;

Spunt, Sheri L. ;

Skapek, Stephen X. .

PEDIATRIC BLOOD & CANCER, 2013, 60 (06) :1001-1008

[16] Results of treatment for soft tissue sarcoma in childhood and adolescence:: A final report of the German cooperative soft tissue sarcoma study CWS-86 [J].

Koscielniak, E ;

Harms, D ;

Henze, G ;

Jürgens, H ;

Gadner, H ;

Herbst, M ;

Klingebiel, T ;

Schmidt, BF ;

Morgan, M ;

Knietig, R ;

Treuner, J .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3706-3719

[17]

KOSCIELNIAK E, 1992, CANCER, V70, P2557, DOI 10.1002/1097-0142(19921115)70:10<2557::AID-CNCR2820701027>3.0.CO

[18]

2-8

[19] The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma A report from the Children's Oncology Group [J].

Malempati, Suman ;

Weigel, Brenda J. ;

Chi, Yueh-Yun ;

Tian, Jing ;

Anderson, James R. ;

Parham, David M. ;

Teot, Lisa A. ;

Rodeberg, David A. ;

Yock, Torunn I. ;

Shulkin, Barry L. ;

Spunt, Sheri L. ;

Meyer, William H. ;

Hawkins, Douglas S. .

CANCER, 2019, 125 (02) :290-297

[20]

MAURER HM, 1993, CANCER-AM CANCER SOC, V71, P1904, DOI 10.1002/1097-0142(19930301)71:5<1904::AID-CNCR2820710530>3.0.CO

← 1 2 3 4 →